Woodline Partners’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.1M Sell
344,256
-156,767
-31% -$8.43M 0.07% 353
2025
Q4
$24.3M Hold
501,023
0.09% 271
2025
Q3
$15.3M Hold
501,023
0.07% 338
2025
Q2
$11.1M Sell
501,023
-290,000
-37% -$6.07M 0.06% 408
2025
Q1
$14.7M Buy
791,023
+305,950
+63% +$5.1M 0.1% 285
2024
Q4
$6.42M Buy
485,073
+25,094
+5% +$608K 0.04% 434
2024
Q3
$15.4M Buy
459,979
+207,613
+82% +$7.09M 0.13% 223
2024
Q2
$6.32M Sell
252,366
-256,473
-50% -$5.97M 0.06% 312
2024
Q1
$11.5M Sell
508,839
-686,135
-57% -$16.2M 0.11% 240
2023
Q4
$25.6M Buy
1,194,974
+354,153
+42% +$6.11M 0.28% 112
2023
Q3
$15.1M Sell
840,821
-193,728
-19% -$3.7M 0.18% 164
2023
Q2
$21M Buy
1,034,549
+574,987
+125% +$11.7M 0.25% 114
2023
Q1
$10M Sell
459,562
-187,983
-29% -$4.57M 0.14% 199
2022
Q4
$20.1M Sell
647,545
-462,617
-42% -$13.1M 0.27% 105
2022
Q3
$28.3M Buy
1,110,162
+189,524
+21% +$4.44M 0.4% 68
2022
Q2
$18.7M Buy
920,638
+86,711
+10% +$1.92M 0.29% 109
2022
Q1
$20.6M Buy
833,927
+223,946
+37% +$6.78M 0.33% 88
2021
Q4
$21.2M Sell
609,981
-403,975
-40% -$12.8M 0.3% 88
2021
Q3
$27.5M Buy
1,013,956
+473,904
+88% +$12M 0.45% 57
2021
Q2
$14M Buy
540,052
+111,205
+26% +$2.67M 0.26% 102
2021
Q1
$9.24M Buy
+428,847
New +$10.8M 0.21% 124

Other funds holding ANAB

Woodline Partners's ANAB Position: Q1 2026 in Review

Woodline Partners reduced its AnaptysBio (ANAB) stake by 31% in Q1 2026, selling an estimated $8.43M and leaving 344,256 shares worth $19.1M. The position accounts for 0.07% of the portfolio, ranked #353.

Woodline Partners first reported a position in ANAB in Q1 2021 and has held it in 21 quarters since. The position peaked at $28.3M in Q3 2022. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Woodline Partners held 344,256 shares of AnaptysBio worth $19.1M as of Q1 2026.
  • Woodline Partners sold 156,767 AnaptysBio shares in Q1 2026, an estimated $8.43M.
  • AnaptysBio made up 0.07% of Woodline Partners's portfolio in Q1 2026, its #353 holding.
  • Woodline Partners first reported a position in AnaptysBio in Q1 2021 and has held it in 21 quarters since.
  • Woodline Partners's AnaptysBio position peaked at $28.3M in Q3 2022.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.